Optimal patient selection on the basis of prostate size, presence of a median lobe, and patient preferences is key to success for various minimally invasive surgical treatments for benign prostatic hyperplasia (BPH), including Rezūm, UroLift, a temporary implantable nitinol device, prostate artery embolization, and Optilume BPH balloon dilatation.
European urology focus. 2025 May 09 [Epub ahead of print]
Peter Ka-Fung Chiu, Brian W H Siu, Cosimo De Nunzio
SH Ho Urology Centre, Department of Surgery, Chinese University of Hong Kong, Hong Kong, China. Electronic address: ., SH Ho Urology Centre, Department of Surgery, Chinese University of Hong Kong, Hong Kong, China., Department of Urology, Sant' Andrea Hospital, Sapienza University of Rome, Rome, Italy.